1.56

1.89% -0.03

Pre-market: 1.63 0.07 +4.49%

Aclaris Therapeutics Inc (ACRS)

Overview News Price History Option Chain Financials Why ACRS Down? Discussions Forecast

Aclaris Therapeutics Inc stock is traded at $1.56, with a volume of 1.07M. It is down -1.89% in the last 24 hours and down -29.09% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Previous Close:

$1.59

Open:

$1.57

24h Volume:

1.07M

Relative Volume:

1.28

Market Cap:

$168.71M

Revenue:

$27.08M

Net Income/Loss:

$-37.00M

P/E Ratio:

-3.00

EPS:

-0.52

Net Cash Flow:

$-18.46M

1W Performance:

-14.29%

1M Performance:

-29.09%

6M Performance:

+32.20%

1Y Performance:

+24.80%

1-Day Range:

$1.54

$1.67

1-Week Range:

$1.54

$2.0275

52-Week Range:

$0.9515

$5.17

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name

Aclaris Therapeutics Inc

Sector

Healthcare (1169)

Industry

Diagnostics & Research (61)

Phone

484-324-7933

Address

701 LEE ROAD, WAYNE, PA

Employee

Twitter

@aclaristx

Next Earnings Date

2025-02-24

Latest SEC Filings

ACRS's Discussions on Twitter

Compare ACRS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRS Aclaris Therapeutics Inc	1.56	168.71M	27.08M	-37.00M	-18.46M	-0.52
TMO Thermo Fisher Scientific Inc	508.90	191.99B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	204.09	145.87B	23.88B	3.90B	5.30B	5.28
A Agilent Technologies Inc	117.33	33.47B	6.53B	1.26B	1.31B	4.35
IDXX Idexx Laboratories Inc	406.29	33.04B	3.90B	887.87M	798.08M	10.67
IQV Iqvia Holdings Inc	181.43	31.99B	15.41B	1.37B	2.11B	7.50

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-19-24	Upgrade	BTIG Research	Neutral → Buy
Nov-19-24	Upgrade	Jefferies	Hold → Buy
Nov-19-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-18-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-01-22	Initiated	Goldman	Buy
Oct-06-22	Initiated	BTIG Research	Buy
Jul-23-21	Resumed	Jefferies	Buy
Jun-15-21	Initiated	Piper Sandler	Overweight
Apr-21-21	Initiated	H.C. Wainwright	Buy
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform
Mar-28-18	Resumed	Leerink Partners	Outperform
Feb-09-18	Initiated	Guggenheim	Buy
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
Nov-29-16	Initiated	Leerink Partners	Outperform
Sep-30-16	Initiated	JMP Securities	Mkt Outperform
Jun-10-16	Initiated	Guggenheim	Buy
Nov-02-15	Initiated	Citigroup	Buy
Nov-02-15	Initiated	Jefferies	Buy

View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

Mar 12, 2025

Aclaris Reports 2024 Financial Results and Sets Stage for Transformative 2025 - MSN

Mar 12, 2025

Mar 11, 2025

Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion - Investing.com

Mar 11, 2025

Aclaris Therapeutics at Leerink’s Conference: Strategic Pipeline Expansion By Investing.com - Investing.com UK

Mar 11, 2025

Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MSN

Mar 11, 2025

Common Warts Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail

Mar 11, 2025

Mar 09, 2025

Scotiabank Begins Coverage on Aclaris Therapeutics (NASDAQ:ACRS) - Defense World

Mar 09, 2025

Mar 08, 2025

Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025

Scotiabank Initiates Coverage of Aclaris Therapeutics (ACRS) with Sector Outperform Recommendation - Nasdaq

Mar 08, 2025

Mar 07, 2025

Scotiabank sets Aclaris stock target at $15 with new rating - Investing.com

Mar 07, 2025

Scotiabank sets Aclaris stock target at $15 with new rating By Investing.com - Investing.com UK

Mar 07, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St

Mar 07, 2025

Cantor Fitzgerald Predicts ACRS FY2025 Earnings - Defense World

Mar 07, 2025

Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $11.00 - Defense World

Mar 07, 2025

Mar 06, 2025

Aclaris Therapeutics (NASDAQ:ACRS shareholders incur further losses as stock declines 12% this week, taking three-year losses to 88% - Simply Wall St

Mar 06, 2025

Cantor Fitzgerald Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-Buy - Defense World

Mar 06, 2025

Mar 05, 2025

Aclaris Therapeutics plans $300M mixed shelf offering - MSN

Mar 05, 2025

Mar 04, 2025

Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewswire

Mar 04, 2025

Will Aclaris Therapeutics Reveal New Pipeline Updates at March Healthcare Conferences? - StockTitan

Mar 04, 2025

This Aclaris Therapeutics Insider Increased Their Holding By 1,537% Last Year - Yahoo Finance

Mar 04, 2025

Mar 03, 2025

JAK Inhibitors Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - GlobeNewswire Inc.

Mar 03, 2025

Aclaris Therapeutics Inc (NASDAQ: ACRS): Hidden Gems In A Time Of Volatility - Stocks Register

Mar 03, 2025

Hair Loss Treatment Market Hits New High | Major Giants Follica, Theradome, Histogen, Aclaris Therapeutics - Newstrail

Mar 03, 2025

Q1 Earnings Forecast for ACRS Issued By Leerink Partnrs - Defense World

Mar 03, 2025

Feb 28, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Posts Quarterly Earnings Results - MarketBeat

Feb 28, 2025

Investor Network: Aclaris Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 28, 2025

Feb 27, 2025

Aclaris Therapeutics Inc earnings missed by $0.72, revenue topped estimates - Investing.com

Feb 27, 2025

Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat

Feb 27, 2025

Aclaris Therapeutics reports Q4 EPS ($1.01), consensus (38c) - TipRanks

Feb 27, 2025

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times

Feb 27, 2025

Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan - MSN

Feb 27, 2025

Feb 26, 2025